Our results revealed that the high-risk group had significantly higher expression levels of CD274 and PDCD1, which contributed to identifying DLBCL patients who are susceptible to PD-1 inhibitors [44–46]. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.